https://www.selleckchem.com/pr....oducts/lusutrombopag
Data on the long-term administration of ustekinumab in recommended doses are limited. To assess the real-world, long-term effectiveness of ustekinumab in refractory Crohn's disease (CD). Multi-centre study of CD patients starting ustekinumab at the recommended dose, followed for 1year. Values for the Harvey-Bradshaw Index (HBI), endoscopic activity, C-reactive protein (CRP), and faecal calprotectin (FC) were recorded at baseline and at weeks 26 and 52. Demographic and clinical data, previous treatments, adverse events (AEs) and ho
Like
Comment
Share
